Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168499 · ClinicalTrials.gov registry record · NA
Diet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis
A NA study of IBD (Inflammatory Bowel Disease), sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT07168499: Recruiting NA study of IBD (Inflammatory Bowel Disease), sponsored by Massachusetts General Hospital.
NCT07168499 is a NA study of IBD (Inflammatory Bowel Disease) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 160 participants, above the 103-participant average among 3 other IBD (Inflammatory Bowel Disease) trials with a reported enrollment target (55% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168499, a NA study of IBD (Inflammatory Bowel Disease), is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, immune-mediated disease characterized by recurrent episodes of relapse. The goal of this single site, pragmatic, randomized trial is to answer if combining lifestyle modifications (mindfulness/stress management + nutrition support) with advanced therapies for induction and maintenance of clinical remission in CD and UC as evaluated by disease activity scores in patients with active CD and UC. Researchers will compare 4 study arms (Group 1, Group 2, Group 3, and Group 4) to see if combining lifestyle modifications with advanced therapies for induction and maintenance will show improvement in condition as evaluated by disease activity scores. Groups: 1. Group A - Subjects will receive a visit with an IBD dietician and a visit with an IBD GI psychologist within the first month of advanced therapy initiation and another visit with both parties 4+/-2 weeks after the first intervention visit. 2. Group B - Subjects will receive a visit with an IBD dietician within the first month of advanced therapy initiation and another visit 4+/-2 weeks after the first intervention visit. They will later be offered a visit with an IBD GI psychologist after 3 months (after assessment of our primary outcomes). 3. Group C - Subjects will receive a visit with an IBD psychologist within the first month of advanced therapy initiation and another visit with the IBD GI psychologist 4+/-2 weeks after the first intervention visit. They will later be offered a visit with an IBD dietician after 2 months (after assessment of our primary outcomes). 4. Group D - Subjects will be offered a visit with an IBD GI psychologist and IBD dietician after 3 months (after assessment of our primary outcomes). All subjects will be asked to complete a set of questionnaires and have the option to give blood and stool samples throughout the life of their participation in the study at certain visits.
Primary Outcome
Subjects in the intervention arms will show clinically significant improvement in IBD symptoms after week 12 of the treatment period based upon disease activity scores using the Harvey-Bradshaw Disease Activity Index (HBI). For the HBI, a score less than 3 indicates remission while a score of 8-9 reflects severe disease.
Conditions Studied
Interventions
- BEHAVIORAL Stress Management
- BEHAVIORAL Diet Management
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2028-05-01 |
| Phase | NA |
What NCT07168499 shows while recruiting
NCT07168499 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 3 other IBD (Inflammatory Bowel Disease) trials with a reported enrollment target (55% higher).
The record links to 1 condition, with IBD (Inflammatory Bowel Disease) appearing as the primary indexed condition, and to 2 interventions - of which Stress Management is the first listed.
NCT07168499 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07168499 about?
NCT07168499 is a clinical study titled "Diet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis". Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, immune-mediated disease characterized by recurrent episodes of relapse. The goal of this single site, pragmatic, randomized trial is to answer if combining lifestyle modifications (mindfu...
What is the current status of trial NCT07168499?
This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2025-09-15. Estimated completion is 2028-05-01.
What conditions does trial NCT07168499 study?
This clinical trial studies the following conditions: IBD (Inflammatory Bowel Disease).
What interventions are being tested in trial NCT07168499?
The interventions under investigation include: Stress Management (BEHAVIORAL), Diet Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT07168499?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07168499 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IBD (Inflammatory Bowel Disease)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI